Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects

Expert Opinion on Drug Safety

Volumn 10, Issue 4, 2011, Pages 509-519

  Huennemeyer, Andreas ^a   Nassr, Nassr ^a   Bredenbröker, Dirk ^a   Lahu, Gezim ^a  

^a Nycomed GmbH   (Germany)

Author keywords

cardiac safety; healthy volunteers; phosphodiesterase 4 inhibition; QTc interval; roflumilast

Indexed keywords

DRUG METABOLITE; MOXIFLOXACIN; PLACEBO; ROFLUMILAST; ROFLUMILAST N OXIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FATALITY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART RATE; HEART REPOLARIZATION; HEMATOLOGIC DISEASE; HUMAN; HUMAN EXPERIMENT; LYMPHATIC SYSTEM DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NORMAL HUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PR INTERVAL; QRS COMPLEX; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SENSORY DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN APPENDAGE DISEASE; SKIN DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; UROGENITAL TRACT DISEASE;

ADOLESCENT; ADULT; AMINOPYRIDINES; BENZAMIDES; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79958840162     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.581659     Document Type: Article

References (31)

1. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94
2. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703
3. Hermann R, Lahu G, Hauns B, et al. "Total PDE4 inhibitory activity": a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions. Eur Respir J 2006;28:436s
4. Lahu G, Hunnemeyer A, von Richter O, et al. Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol 2008;48:1339-49
5. von Richter O, Lahu G, Huennemeyer A, et al. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. Clin Pharmacokinet 2007;46:613-22 (Pubitemid 47025361)
6. David M, Zech K, Seiberling M, et al. Roflumilast, a novel, oral, selective PDE4 inhibitor, shows high oral bioavailability. J Allergy Clin Immunol 2004;113:S220-1
7. Bethke TD, Boehmer GM, Hermann R, et al. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 2007;47:26-36 (Pubitemid 44973995)
8. Hermann R, Nassr N, Lahu G, et al. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet 2007;46:403-16 (Pubitemid 46686466)
9. Lahu G, Huennemeyer A, Herzog R, et al. Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. Int J Clin Pharmacol Ther 2009;47:236-45
10. Lahu G, Nassr N, Herzog R, et al. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-Oxide. J Clin Pharmacol 2010; [Epub ahead of print]
11. Nassr N, Huennemeyer A, Herzog R, et al. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol 2009;68:580-7
12. The E14 Implementation Working Group. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH Guidelines E14; 2005
13. Bundschuh DS, Eltze M, Barsig J, et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-90 (Pubitemid 32242588)
14. Card GL, England BP, Suzuki Y, et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 2004;12:2233-47 (Pubitemid 39593200)
15. Jones NA, Boswell-Smith V, Lever R, et al. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 2005;18:93-101 (Pubitemid 40092659)
16. Schmidt BM, Kusma M, Feuring M, et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001;108:530-6 (Pubitemid 32978022)
17. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003;63:2575-94 (Pubitemid 37491561)
18. Okumura S, Suzuki S, Ishikawa Y. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: effects of targeted disruption of the type 5 adenylyl cyclase gene. J Pharmacol Sci 2009;109:354-9
19. Singh K, Xiao L, Remondino A, et al. Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol 2001;189:257-65 (Pubitemid 33063293)
20. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 2007;100:1569-78 (Pubitemid 46897260)
21. Ding B, Abe J, Wei H, et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 2005;111:2469-76 (Pubitemid 40696135)
22. Yan C, Miller CL, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 2007;100:489-501 (Pubitemid 46673258)
23. Geelen P, Drolet B, Rail J, et al. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000;102:275-7 (Pubitemid 30457575)
24. Morganroth J, Ilson BE, Shaddinger BC, et al. Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 2004;93:1378-83, A6 (Pubitemid 38692465)
25. Roflumilast: assessment of nonclinical cardiovascular safety. Data on file, Nycomed GmbH (previously Altana Pharma AG 177/2003 2003
26. Data on file, Nycomed GmbH (previously Altana Pharma AG) 37/2000; 2000
27. Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009;32:359-78
28. Malik M, Hnatkova K, Schmidt A, et al. Electrocardiographic QTc changes due to moxifloxacin infusion. J Clin Pharmacol 2009;49:674-83
29. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001;24:323-51 (Pubitemid 32417533)
30. Rabe KF, Bateman ED, ODonnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71 (Pubitemid 41140331)
31. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61 (Pubitemid 47057851)